Skip to main content

Day: April 16, 2024

Globus Medical Schedules First Quarter Earnings Release and Conference Call

AUDUBON, Pa., April 16, 2024 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, May 7, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at https://www.investors.globusmedical.com/news-events/events-webcasts. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation...

Continue reading

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nations As previously reported, PaxMedica recently executed final registration and validation batches of PAX-101 (an IV form of suramin) in preparation for a future NDA submission as an orphan designated drugTARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region...

Continue reading

Mercer International Inc. Announces Conference Call for First Quarter 2024 Results

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) — Mercer International (NASDAQ: MERC) will release its first quarter results for the period ending March 31, 2024 on Thursday, May 9, 2024, after the close of the market. Juan Carlos Bueno, President and Chief Executive Officer and Richard Short, Chief Financial Officer and Secretary, will be hosting a conference call on Friday, May 10, 2024, at 10:00 am ET to discuss the results. The conference call will be available to interested parties live over the Internet through a webcast by clicking on or copying and pasting the following link into their web browser: https://edge.media-server.com/mmc/p/tdezetkf A link to the webcast is also available on the Investor Relations section of the Company’s webpage. For those unable to participate in the live webcast, a replay of the webcast will be archived...

Continue reading

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase shares of voting common stock. All shares of voting common stock and pre-funded warrants to be sold in the offering will be offered by TScan. TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering. The offering is...

Continue reading

Sezzle to Participate in Upcoming Investor Conferences

Minneapolis, MN, April 16, 2024 (GLOBE NEWSWIRE) — Sezzle Inc. (NASDAQ:SEZL) (Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, today announced that the Company’s management team will participate in the following investor conferences: May 16, 2024: Sezzle will participate in Needham’s 19th Annual Technology, Media, & Consumer Conference. May 22-23, 2024: management will attend B. Riley Securities’ 24th Annual Institutional Investor Conference. June 25, 2024: the Company will take part in the Northland Growth Conference 2024. Contact InformationLee Brading, CFA Investor Relations +651 240 6001 investorrelations@sezzle.com Erin Foran Media Enquiries  +651 403 2184 erin.foran@sezzle.com  About Sezzle Inc. Sezzle is a certified B Corporation on a mission to financially empower...

Continue reading

Twin Disc Announces Details of Fiscal 2024 Third Quarter Earnings Release, Webcast, and Conference Call

MILWAUKEE, April 16, 2024 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN), today announced that it will release its fiscal 2024 third-quarter results at approximately 8:00 am Eastern on April 30, 2024, and host a webcast and conference call to discuss those results at 9:00 am Eastern. Following their prepared remarks, the Company will host a question-and-answer session with the investment community. The live audio webcast will be available on Twin Disc’s website at https://ir.twindisc.com. To participate in the conference call, please dial (800) 715-9871 approximately ten minutes before the call is scheduled to begin. A replay of the webcast will be available at https://ir.twindisc.com shortly after the call until April 29, 2025. About Twin DiscTwin Disc, Inc. designs, manufactures and sells marine and heavy-duty off-highway...

Continue reading

Oil-Dri to Acquire Ultra Pet in Strategic Move to Compete in Rapidly Growing Crystal Cat Litter Market

CHICAGO, April 16, 2024 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC) (“Oil-Dri”), a leading manufacturer of sorbent minerals including clay-based cat litter, announced today that it has entered into a definitive agreement to acquire privately-held Ultra Pet Company, Inc. (“Ultra Pet”), a prominent supplier of silica gel-based crystal cat litter. Under the terms of the agreement, Oil-Dri will acquire Ultra Pet for $46 million in cash. Oil-Dri plans to finance this acquisition through a combination of cash-on-hand and its existing credit facilities. The board of directors of Oil-Dri and the managers of Ultra Pet’s parent company have unanimously approved the transaction which is expected to close in Oil-Dri’s fourth quarter of fiscal year 2024, after satisfaction of customary closing conditions. Oil-Dri expects this...

Continue reading

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe atopic dermatitis (AD) Type C meeting in AD and End-of-Phase 2 (EoP2) meeting in asthma have been scheduled with the U.S. Food and Drug Administration (FDA) in Q2 2024 to discuss trial results and proposed registrational programs Granted Simcere the exclusive rights to develop, manufacture, and commercialize rademikibart for all indications in Greater China. Simcere is actively engaged with China’s Center for Drug Evaluation (CDE) regarding the potential NDA filing for marketing approval in China for treatment with rademikibart in patients with AD Cash, cash equivalents and short-term investments of $118.7 million expected to support planned...

Continue reading

Zapp EV Announces Reverse Stock Split

LONDON, April 16, 2024 (GLOBE NEWSWIRE) — Zapp Electric Vehicles Group Limited (Nasdaq: ZAPP) (“Zapp EV” or the “Company”), owner of “Zapp”, the British electric vehicle brand on a mission to revolutionize personal urban mobility, today announced that its shareholders approved at the Company’s annual general meeting on April 11, 2024, and that the Company will effect, a consolidation of its authorized share capital at a ratio of 1-for-20 (the “Reverse Stock Split”), in order that the share capital of the Company be amended from US$50,000 divided into 500,000,000 ordinary shares of a nominal or par value of US$0.0001 to US$50,000 divided into 25,000,000 ordinary shares of a nominal or par value of US$0.002 (the latter, the “New Ordinary Shares”). The Reverse Stock Split will be effective at 4:01 p.m. (EDT) on Monday, April 22, 2024,...

Continue reading

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.